Sign in Subscribe
United States. Securities and Exchange Commission

Seattle Genetics Inc. Files SEC Form SC 13D - Beneficial Ownership Disclosure

Strategic Insights

— 1 min read

Seattle Genetics Inc. has recently filed a U.S. Securities and Exchange Commission (SEC) form SC 13D, disclosing beneficial ownership of certain registered equity securities. This filing, posted on May 8, 2015, provides essential information about the company's equity holdings. As a biotechnology company specializing in biological products, Seattle Genetics Inc. is subject to SEC regulations governing beneficial ownership. With the SIC code 2836, the company falls under the category of Biological Products (No Diagnostic Substances).

Key Takeaways:

  • The SEC filing, Form SC 13D, discloses beneficial ownership of more than 5% of a class of registered equity securities, which is a mandatory filing for issuers under SEC regulations.
  • The filing requires the disclosure of any material changes in the facts set forth in the Schedule, prompting the need for amendments on Schedule 13D.
  • The Commission's rules define "beneficial owner" as any person who directly or indirectly shares voting power or investment power in the securities.
  • Seattle Genetics Inc.'s filing is a formal document submitted to the SEC, providing detailed information about the company's equity holdings.
  • The filing is a requirement under SEC rules for companies like Seattle Genetics Inc. that have a class of registered equity securities with a minimum of 2,000 holders.
  • The company's filing is publicly available on the SEC website, offering stakeholders access to detailed information about the company's equity ownership.

Statistics:

  • The filing, Form SC 13D, is a single document submitted by Seattle Genetics Inc. to the SEC.
  • The document was filed on May 8, 2015, and is publicly available on the SEC website.
  • The company's SIC code is 2836, indicating its category as Biological Products (No Diagnostic Substances).
  • Seattle Genetics Inc. has a contact address of 21823 30TH DRIVE SE, SUITE, BOTHELL WA 98021, and a phone number of 4255274000.

Sources:

  • Form SC 13D filing by Seattle Genetics Inc. on May 8, 2015 (SEC file number 0001144204-15-028584).
  • SEC website (http://www.sec.gov/Archives/edgar/data/1060736/0001144204-15-028584-index.html).
  • News article at Pharma Business Week (no specific date, 2015).

Read more